Cynapsus Therapeutics Inc. (CYNA): OrbiMed Advisors Adds To Its Stake

Page 2 of 7 – SEC Filing
CUSIP No. 23257Y859
 SCHEDULE 13G
Page 2 of 7 Pages
   
1
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
OrbiMed Capital GP V LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) o
 
 
3
SEC USE ONLY
4
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
0
6
SHARED VOTING POWER
1,620,325
7
SOLE DISPOSITIVE POWER
0
8
SHARED DISPOSITIVE POWER
1,620,325
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,620,325
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
13.2%(1)
12
TYPE OF REPORTING PERSON (See Instructions)
OO
(1) This percentage is calculated based upon 12,316,441 shares of the Issuer’s Common Stock (“Shares”) outstanding, as set forth in the Issuer’s Form 10-Q, dated May 10, 2016, filed with the Securities and Exchange Commission on May 11, 2016.

Follow Cynapsus Therapeutics Inc.